Department of Medicine, Montefiore Medical Center, Division of Cardiology, Albert Einstein College of Medicine, Bronx, New York, USA.
Clin Cardiol. 2012 Oct;35(10):632-40. doi: 10.1002/clc.22036. Epub 2012 Jun 28.
Data regarding reperfusion strategies, adherence to national guidelines, and in-hospital mortality in ST-elevation myocardial infarction (STEMI) patients age ≥80 years are limited. The aim of this study was to determine current reperfusion trends, medical treatment, and in-hospital mortality during STEMI in older adults.
Among patients aged 80 or above presenting with STEMI, adherence to guidelines, length of stay, and in-hospital mortality would be better in those receiving reperfusion versus those who did not.
Using the Get With The Guidelines-Coronary Artery Disease (GWTG-CAD) database, we examined care and in-hospital outcomes of STEMI patients ≥80 years old. Use of evidence-based therapies and quality measures were analyzed by reperfusion strategies.
A total of 5339 patients age ≥80 years hospitalized with STEMI were included. Of these, 42.8% (n = 2285) underwent primary percutaneous coronary intervention (PPCI), 4.8% (n = 255) underwent thrombolysis (TL), and 52.4% (n = 2799) received no reperfusion (NR). Patients with NR were more likely to be older, female, have lower body mass index, and higher prevalence of renal insufficiency and heart failure compared with PPCI or TL patients. During the last decade, there was a significant increase in the use of PPCI compared with TL as the main reperfusion strategy in this population. Adjusted in-hospital mortality in PPCI patients was lower compared with NR patients (odds ratio [OR]: 0.41, 95% confidence interval [CI]: 0.35-0.49); also, patients undergoing PPCI or TL had lower mortality compared with NR patients (OR: 0.47, 95% CI: 0.40-0.55).
Among patients ≥80 years old admitted with STEMI to GWTG-CAD hospitals, less than half undergo mechanical or pharmacological reperfusion. However, the proportion of patients undergoing PPCI has increased substantially over the 8-year study period. Patients undergoing PPCI or TL had lower in-hospital mortality compared with the NR strategy.
关于再灌注策略、对国家指南的依从性以及年龄≥80 岁 ST 段抬高型心肌梗死(STEMI)患者院内死亡率的数据有限。本研究的目的是确定老年人 STEMI 中的再灌注趋势、药物治疗和院内死亡率。
在年龄≥80 岁的 STEMI 患者中,与未接受再灌注的患者相比,接受再灌注的患者更能遵守指南、延长住院时间和降低院内死亡率。
我们使用 Get With The Guidelines-Coronary Artery Disease(GWTG-CAD)数据库,检查了年龄≥80 岁 STEMI 患者的护理和院内结局。通过再灌注策略分析了证据为基础的治疗和质量指标的使用情况。
共纳入 5339 名年龄≥80 岁的 STEMI 住院患者。其中,42.8%(n=2285)接受了直接经皮冠状动脉介入治疗(PPCI),4.8%(n=255)接受了溶栓治疗(TL),52.4%(n=2799)未接受再灌注(NR)。与 PPCI 或 TL 患者相比,NR 患者年龄更大、女性更多、体重指数更低、肾功能不全和心力衰竭的发生率更高。在过去十年中,这种人群中 PPCI 的使用率与 TL 相比显著增加。与 NR 患者相比,PPCI 患者的院内死亡率降低(比值比[OR]:0.41,95%置信区间[CI]:0.35-0.49);接受 PPCI 或 TL 的患者与 NR 患者相比,死亡率也较低(OR:0.47,95%CI:0.40-0.55)。
在接受 GWTG-CAD 医院治疗的年龄≥80 岁的 STEMI 患者中,不到一半的患者接受机械或药物再灌注。然而,在 8 年的研究期间,接受 PPCI 的患者比例大幅增加。与 NR 策略相比,接受 PPCI 或 TL 的患者院内死亡率较低。